Key result
Kawasaki disease and Kawasaki-like disease have symptoms overlapping with COVID-19, requiring prompt diagnosis and treatment with IVIG and aspirin to prevent coronary artery aneurysms.
Why the study?
Kawasaki disease symptoms overlap with multisystem inflammatory disease seen in COVID-19, adding to difficulties in timely diagnosis and treatment to prevent coronary artery aneurysms.
Timely diagnosis and treatment of Kawasaki disease are critical to prevent coronary artery aneurysms, especially given the diagnostic challenges posed by symptom overlap with COVID-19.
Kawasaki-like presentations in children may indicate COVID-19; leaves open whether SARS-CoV-2 triggers Kawasaki disease.
Kawasaki disease is an acute, self-limiting vasculitis in children. Early treatment is necessary to prevent cardiovascular complications. The acute phase of Kawasaki disease may present with hemodynamic instability. An association between viral respiratory infections and Kawasaki disease has been reported. Studies have shown that Kawasaki and Kawasaki-like disease may be associated with and have symptoms overlapping COVID-19. Children with COVID-19 may present as Kawasaki-like disease with pediatric inflammatory multisystem syndrome, or macrophage activation syndrome. Clinicians need to be aware of the early diagnosis and management of Kawasaki disease to prevent the development of coronary artery aneurysms. The symptoms overlap of multisystem inflammatory disease seen in COVID-19 adds to the difficulties in timely diagnosis and treatment. Children with Kawasaki disease require regular follow-up plans for coronary artery aneurysms. This adds to the difficulties during the changed environment of COVID-19 for control and prevention. Missed diagnosis and early treatment of Kawasaki disease with immunoglobulin and aspirin results in the development of coronary artery aneurysm in up to 25% of cases, with grave consequences. Here, we briefly review the management of typical and atypical Kawasaki disease which has symptoms overlapping with the multisystem inflammatory disease as seen in COVID-19.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a review in Kawasaki Disease and COVID-19. Management strategies for Kawasaki Disease was evaluated. Kawasaki disease and Kawasaki-like disease have symptoms overlapping with COVID-19, requiring prompt diagnosis and treatment with IVIG and aspirin to prevent coronary artery aneurysms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: